Drug Trial Radar · NCT03037385
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
590
Actual
Start
Mar 17, 2017
Primary completion
Mar 21, 2024
Study completion Mar 21, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.
Conditions
- RET-altered Non Small Cell Lung Cancer
- Medullary Thyroid Cancer
- RET-altered Papillary Thyroid Cancer
- RET-altered Colon Cancer
- RET-altered Solid Tumors
- Lung Neoplasm
- Carcinoma, Non-Small-Cell Lung
- Thyroid Diseases
- Thyroid Neoplasm
- Thyroid Cancer, Papillary
- Carcinoma, Neuroendocrine
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms by Site
- Neoplasms
- Lung Diseases
- Respiratory Tract Disease
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Endocrine System Diseases
- Endocrine Gland Neoplasm
- Head and Neck Neoplasms
- Adenocarcinoma, Papillary
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- Neuroendocrine Tumors
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Colonic Neoplasms
- Colorectal Neoplasms
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasm
- Digestive System Disease
- Gastrointestinal Disease
- Colonic Diseases
- Intestinal Disease
Interventions
pralsetinib (BLU-667)Drug
pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of PralsetinibTime frame: Up to approximately 30.8 months
- Phase 1 and Phase 2: Number of Participants With AEs and Serious AEs (SAEs)Time frame: From Cycle 1 Day 1 up to 30 days after the final dose of study drug (up to approximately 6.7 years)
- Phase 2: Overall Response Rate (ORR)Time frame: Up to approximately 79.8 months
Locations
71 sites in 13 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
UC Irvine Medical Center
Orange, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
Mayo Clinic-Jacksonville
Jacksonville, Florida
Sylvester Comprehensive Cancer Center
Miami, Florida
Maryland Oncology Hematology, P.A.
Columbia, Maryland
Massachusetts General Hospital.
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Washington University School of Medicine in St. Louis
St Louis, Missouri
Albany Medical Center
Albany, New York
Weill Cornell Medical College-New York Presbyterian Hospital
New York, New York
Oregon Health & Science University
Portland, Oregon
Texas Oncology-Austin Midtown
Austin, Texas
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Seattle Cancer Care Alliance
Seattle, Washington
Antwerp University Hospital
Edegem, Belgium
Beijing Cancer Hospital
Beijing, China
Beijing Cancer Hospital
Beijing, China
The affiliated Cancer Hospital, School of Medicine, UESTC
Chengdu, China
West China Hospital, Sichuan University
Chengdu, China
Chongqing Cancer Hospital
Chongqing, China
Fujian Provincial Cancer Hospital
Fuzhou, China
First Affiliated Hospital of Gannan Medical University
Ganzhou, China
Sun Yet-sen University Cancer Center
Guangzhou, China
Guangdong General Hospital
Guangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Jinan Central Hospital
Jinan, China
Gansu Cancer Hospital
Lanzhou, China
Fudan University Shanghai Cancer Center
Shanghai, China
Fudan University Shanghai Cancer Center
Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
Tianjing, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Henan Cancer Hospital
Zhengzhou, China
Institut Bergonie
Bordeaux, France
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez
Lille, France
Centre Léon Bérard
Lyon, France
Centre Antoine Lacassagne
Nice, France
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.